Generics Bulletin Explains: Sandoz’s Spinoff From Novartis
Ahead Of Capital Markets Day On 8 June, The Story So Far For The Spinoff Of Sandoz
Ahead of a Sandoz capital markets day on 8 June, Generics Bulletin explains what we know so far about the firm’s spinoff from parent company Novartis – as well as the questions that the companies are yet to answer.
You may also be interested in...
With around a month to go until Sandoz is expected to become a standalone company following its spinoff from parent Novartis, the firm has published additional financial information ahead of a shareholders meeting in mid-September.
In a year that has seen significant changes throughout our generics and biosimilars industry ranking, the top 10 has welcomed two Indian off-patent leaders after two other firms dropped out of the top table. We delve into what has changed in the first instalment of this year’s Generics Bulletin Top 50.
Looking back over the second quarter of 2023, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include strategic updates from some of the off-patent industry’s biggest players, several exclusive interviews, and the build-up to the second wave of biosimilar competition to Humira in the US.